Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by SizzlinSteakson Dec 01, 2017 9:20am

72 Views

Post# 27070928

RE:RE:RE:RE:Cannabis investors

For those that cannot do the math.... a $1 billion dollar valuation would be worth approx. $5.95 per share based on 129 million shares outstanding plus the additional 39 million shares being added by the private placement. Not sure how many options and warrants are out there so it could equate to slightly. Nonetheless, it's a long way from where we are now.

SizzlinSteaks wrote: Closing of the PP and annoucment of the initiation of phase 2 will be pivotal for this company. I am in another pharmeceutical and had a long conversation with the CEO and he informed me that average phase 2 valuation is worth $1 billion dollars. Do the numbers... this company is a screaming buy. Valuation is going waaaaay up in short order. Now is the time to get in, not after the close of the PP and announcement of phase 2. You will be paying a lot more.

KushMan wrote: The Company intends to use the net proceeds of the Offering to advance its Phase 2 clinical program evaluating the use of cannabidiol in the prevention of graft versus host disease, as well as for general corporate purposes. Completion of the Company’s Phase 2 program will take approximately eight months, and is required by the FDA prior to the initiation of a pivotal Phase 3 study. The Company anticipates that, following completion of the Phase 2 study, it will initiate the Phase 3 study as quickly as possible.

Read more at https://www.stockhouse.com/news/press-releases/2017/11/22/kalytera-announces-5-million-private-placement-of-convertible-debenture-units#1zEvmFmjILxG1teL.99